474 related articles for article (PubMed ID: 25468724)
1. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.
Hallstensen RF; Bergseth G; Foss S; Jæger S; Gedde-Dahl T; Holt J; Christiansen D; Lau C; Brekke OL; Armstrong E; Stefanovic V; Andersen JT; Sandlie I; Mollnes TE
Immunobiology; 2015 Apr; 220(4):452-9. PubMed ID: 25468724
[TBL] [Abstract][Full Text] [Related]
2. Extravascular hemolysis and complement consumption in Paroxysmal Nocturnal Hemoglobinuria patients undergoing eculizumab treatment.
Subías Hidalgo M; Martin Merinero H; López A; Anter J; García SP; Ataúlfo Gonzalez-Fernández F; Forés R; Lopez-Trascasa M; Villegas A; Ojeda E; Rodríguez de Córdoba S
Immunobiology; 2017 Feb; 222(2):363-371. PubMed ID: 27644115
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab-C5 complexes express a C5a neoepitope in vivo: Consequences for interpretation of patient complement analyses.
Nilsson PH; Thomas AM; Bergseth G; Gustavsen A; Volokhina EB; van den Heuvel LP; Barratt-Due A; Mollnes TE
Mol Immunol; 2017 Sep; 89():111-114. PubMed ID: 28610663
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
[TBL] [Abstract][Full Text] [Related]
5. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.
Peffault de Latour R; Fremeaux-Bacchi V; Porcher R; Xhaard A; Rosain J; Castaneda DC; Vieira-Martins P; Roncelin S; Rodriguez-Otero P; Plessier A; Sicre de Fontbrune F; Abbes S; Robin M; Socié G
Blood; 2015 Jan; 125(5):775-83. PubMed ID: 25477495
[TBL] [Abstract][Full Text] [Related]
6. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
7. Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia.
DeZern AE; Brodsky RA
Hematol Oncol Clin North Am; 2015 Jun; 29(3):479-94. PubMed ID: 26043387
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.
Sica M; Rondelli T; Ricci P; De Angioletti M; Risitano AM; Notaro R
J Hematol Oncol; 2017 Jun; 10(1):126. PubMed ID: 28629435
[TBL] [Abstract][Full Text] [Related]
9. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.
Risitano AM
Immunobiology; 2012 Nov; 217(11):1080-7. PubMed ID: 22964233
[TBL] [Abstract][Full Text] [Related]
10. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
Heitlinger E
Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
[TBL] [Abstract][Full Text] [Related]
11. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
12. Drugs that inhibit complement.
Schrezenmeier H; Höchsmann B
Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
Schatz-Jakobsen JA; Zhang Y; Johnson K; Neill A; Sheridan D; Andersen GR
J Immunol; 2016 Jul; 197(1):337-44. PubMed ID: 27194791
[TBL] [Abstract][Full Text] [Related]
14. Neutrophil activation and nucleosomes as markers of systemic inflammation in paroxysmal nocturnal hemoglobinuria: effects of eculizumab.
van Bijnen ST; Wouters D; van Mierlo GJ; Muus P; Zeerleder S
J Thromb Haemost; 2015 Nov; 13(11):2004-11. PubMed ID: 26333021
[TBL] [Abstract][Full Text] [Related]
15. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.
Harder MJ; Kuhn N; Schrezenmeier H; Höchsmann B; von Zabern I; Weinstock C; Simmet T; Ricklin D; Lambris JD; Skerra A; Anliker M; Schmidt CQ
Blood; 2017 Feb; 129(8):970-980. PubMed ID: 28028023
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
17. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Wong EK; Kavanagh D
Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
[TBL] [Abstract][Full Text] [Related]
18. Current and future pharmacologic complement inhibitors.
Risitano AM
Hematol Oncol Clin North Am; 2015 Jun; 29(3):561-82. PubMed ID: 26043392
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
20. Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab.
Vekemans MC; Lambert C; Ferrant A; Saussoy P; Havelange V; Debiève F; Van Den Neste E; Michaux L
Blood Coagul Fibrinolysis; 2015 Jun; 26(4):464-6. PubMed ID: 25688464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]